ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "scleroderma and systemic sclerosis"

  • Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting

    Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study

    Claire Owen1, Gene Ngian2, Kathleen Elford2, Owen Moore3, Mandy Nikpour3, Wendy Stevens3, Susanna Proudman4, Janet Roddy5, Jane Zochling6, Catherine Hill7, Peter Nash8, Allan Sturgess9 and Joanne Sahhar2, 1Rheumatology, Monash Health, Melbourne, Australia, 2Monash Health, Melbourne, Australia, 3St Vincent's Hospital, Melbourne, Australia, 4Royal Adelaide Hospital, Adelaide, Australia, 5Royal Perth Hospital, Perth, Australia, 6Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, 7Queen Elizabeth Hospital, Adelaide, Australia, 8Sunshine Coast Rheumatology, Maroochydore, Australia, 9The St George Hospital, Sydney, Australia

    Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
  • Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting

    Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort

    Tracy M. Frech1, Maureen Murtaugh2, Ami A. Shah3, Jessica K. Gordon4, Victoria K. Shanmugam5, Robyn T. Domsic6, Monique Hinchcliff7, Faye N. Hant8, Shervin Assassi9, Virginia D. Steen10 and Dinesh Khanna11, 1Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, 2Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology, The George Washington University, Washington, DC, 6Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 8Dept of Medicine, Medical Univ of South Carolina, Charleston, SC, 9Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 10Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 11University of Michigan Health System, Ann Arbor, MI

    Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
  • Abstract Number: 877 • 2014 ACR/ARHP Annual Meeting

    Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts

    Tomoaki Higuchi1, Yasushi Kawaguchi1, Kae Takagi1, Akiko Tochimoto1, Yuko Ota2, Yasuhiro Katsumata1, Takahisa Gono1, Masanori Hanaoka1, Yuko Okamoto1, Hidenaga Kawasumi1 and Hisashi Yamanaka3, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 210-22 Kawada-Cha Shinjuku-Ku, Tokyo Women's Medical University, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose Systemic sclerosis (SSc) is a connective tissue disease characterized by inflammation, vasculopathy and fibrosis. Tissue fibrosis directly contributes to mortality or quality of life.…
  • Abstract Number: 772 • 2014 ACR/ARHP Annual Meeting

    RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression

    Zhenghui Li1, Eleni Marmarelis2, Kun Qu3, Lionel Brooks4, Patricia Pioli4, Howard Chang3, Robert Lafyatis5 and Michael Whitfield4, 1Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, 3Stanford University School of Medicine, Stanford, CA, 4Geisel School of Medicine at Dartmouth, Hanover, NH, 5Arthritis Center, Boston University, Boston, MA

    Background/Purpose:   Systemic sclerosis (SSc) is an autoimmune disease with a heterogenous and complex phenotype. Previously, our lab has identified four gene expression subsets (fibroproliferative,…
  • Abstract Number: 770 • 2014 ACR/ARHP Annual Meeting

    Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays

    Frank Schneider1 and Carol A. Feghali-Bostwick2, 1Pathology, University of Pittsburgh, Pittsburghh, PA, 2Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Research on systemic sclerosis (SSc)-associated interstitial lung disease (ILD) has been hindered by the paucity of lung tissues, as SSc patients with lung involvement…
  • Abstract Number: 765 • 2014 ACR/ARHP Annual Meeting

    Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc)

    Pravitt Gourh1, Yoonhee Kim2, Sandeep K. Agarwal3, Filemon K. Tan4, Shervin Assassi4, Javier Martin5, Frank C. Arnett4 and Maureen D Mayes4, 1NIAMS-Rheumatology, National Institutes of Health, Bethesda, MD, 2NIH, Bethesda, MD, 3Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 4Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 5Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain

    Background/Purpose Systemic sclerosis (SSc) is a complex autoimmune disease and several genetic loci increasing SSc susceptibility have been identified with small to modest effect sizes.…
  • Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting

    Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis

    Kristina E.N. Clark1, Henry Lopez2, Xu Shiwen1, Bahja Ahmed Abdi1, George Martin3, Korsa Khan4, David J. Abraham1, Christopher P. Denton5 and Richard J. Stratton1, 1Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 2Murigenics, Vallejo, CA, 3Aero Dap, Vallejo, CA, 4Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, 5Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment.  We analysed dermal…
  • Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting

    Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study

    Thomas Frauenfelder1, Anna Winklehner1, Thi Dan Linh Nguyen1, Rucsandra Dobrota2,3, Stephan Baumüller1, Britta Maurer2 and Oliver Distler2, 1Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, 2Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
  • Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting

    Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction

    Chris T. Derk1, Nora Sandorfi2, Shivani Purohit3 and Christopher Mecoli4, 1Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, 3Rheumatology Division, Department of Medicine, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, 4Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…
  • Abstract Number: 2739 • 2013 ACR/ARHP Annual Meeting

    Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis

    Maureen D. Mayes for the US Scleroderma GWAS Group1, Lara Bossini-Castillo for the Spanish Scleroderma Group2, Olga Gorlova3, Jose Ezequiel Martin4, Xiaodong Zhou1, Wei Chen5, Shervin Assassi1, Jun Ying5, John D. Reveille1, Peter K. Gregersen6, Annette T. Lee7, Maria Teruel8, Francisco David Carmona4, Bobby P.C. Koeleman9, Matthew A. Brown and the Immunochip Consortium10, Christopher P. Denton11, Murray Baron for the Canadian Scleroderma Research Group12, Jasper Broen13, T.R.D.J. Radstake13 and Javier Martin4, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 3Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 5Department of Epidemiology, UT M.D. Anderson Cancer Center, Houston, TX, 6Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 7Genomics & Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 8Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, 9Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, 10Translational Research Institute, University of Queensland Diamantina Institute, Brisbane, Australia, 11Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, 12Rheumatology, Jewish General Hospital, Montreal, QC, Canada, 13Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose : The purpose of this study was to identify SSc risk loci shared with other autoimmune diseases on the Immunochip and to fine-map previously…
  • Abstract Number: 2609 • 2013 ACR/ARHP Annual Meeting

    Dutch Translation and Validation Of The University of California, Los Angeles scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0

    Jessica Meijs1, Daisy Pors1, Theodora P.M. Vliet Vlieland2, Tom W.J. Huizinga1 and Annemie J.M. Schuerwegh1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Gastrointestinal tract (GIT) involvement occurs in approximately 90% of the patients with systemic sclerosis (SSc) and leads to a decrease in health-related quality of…
  • Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting

    Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma  Cohort

    Virginia D. Steen1 and Robyn T. Domsic2, 1Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 2Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Trials of therapy in  pulmonary  hypertension(PH)  have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc)  and  PH  have…
  • Abstract Number: 2576 • 2013 ACR/ARHP Annual Meeting

    Epoprostenol Rescue Therapy In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension

    Adrienne M. Roos1, Christopher Pasarikovski1, Amie T. Kron1, John T. Granton2, Peter Lee3, John Thenganatt4 and Sindhu R. Johnson5, 1Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, 2Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, 3Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, 4Medicine, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Divisions of Respirology and Critical Care Medicine, Toronto, ON, Canada, 5Medicine, Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Epoprostenol has been demonstrated to improve hemodynamics, functional class, and six-minute walk distance (6MWD) in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH…
  • Abstract Number: 2577 • 2013 ACR/ARHP Annual Meeting

    Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients

    Christopher Pasarikovski1, John T. Granton2, Peter Lee3, Adrienne M. Roos1, Amie T. Kron1, Cathy Chau4 and Sindhu R. Johnson5, 1Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, 2Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, 3Lebovic Bldg, Mt. Sinai Hospital, Toronto, ON, Canada, 4Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and idiopathic PAH (IPAH) are conditions with poor survival. There is evidence to suggest that sex…
  • Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort

    Hebah Alhajeri1, Marie Hudson2, Marvin J. Fritzler3, Janet E. Pope4, Canadian Scleroderma Research Group -5 and Murray Baron6, 1Rheumatology, McGill University, Montreal, QC, Canada, 2Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, 3Medicine, University of Calgary, Calgary, AB, Canada, 4St Joseph Health Care, London, ON, Canada, 5Jewish General Hospital, Montreal, QC, Canada, 6Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology